Literature DB >> 10762577

Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate.

R J Oram1, D Marcellino, D Strauss, E Gustafson, C L Talarico, A K Root, P L Sharma, K Thompson, J D Fingeroth, C Crumpacker, B C Herold.   

Abstract

Acyclovir resistance is not a recognized problem among neonates with perinatal herpes simplex virus (HSV) infection. A premature newborn with neurocutaneous HSV infection was treated for 21 days with acyclovir. Disseminated disease recurred 8 days later. A recurrent isolate was resistant to acyclovir and lacked thymidine kinase activity on the basis of a frameshift mutation in the thymidine kinase (tk) gene. Compared with the sensitive isolate obtained during primary infection, replication of the resistant isolate was reduced on primary and permanent cells and even further impaired on cells deleted for cellular tk. The resistant isolate lacked virulence in a murine model of genital infection. Acyclovir-resistant HSV-2 mutants can develop rapidly in neonatal infection and cause clinically significant disease, despite decreased replication in vitro and attenuated virulence in an animal model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762577     DOI: 10.1086/315387

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Use of a single monoclonal antibody to determine the susceptibilities of herpes simplex virus type 1 and type 2 clinical isolates to acyclovir.

Authors:  Christine Chutkowski; Betty Olson; Ann McDonough; James Mahoney; James J McSharry
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

Review 2.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Neonatal herpes encephalitis caused by a virologically confirmed acyclovir-resistant herpes simplex virus 1 strain.

Authors:  Satsuki Kakiuchi; Shigeaki Nonoyama; Hajime Wakamatsu; Kazuhiro Kogawa; Lixin Wang; Hitomi Kinoshita-Yamaguchi; Mutsuyo Takayama-Ito; Chang-Kweng Lim; Naoki Inoue; Masashi Mizuguchi; Takashi Igarashi; Masayuki Saijo
Journal:  J Clin Microbiol       Date:  2012-10-24       Impact factor: 5.948

Review 4.  Neonatal herpes simplex virus infections: where are we now?

Authors:  Clara Thompson; Richard Whitley
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

5.  Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry.

Authors:  B C Herold; I Scordi-Bello; N Cheshenko; D Marcellino; M Dzuzelewski; F Francois; R Morin; V Mas Casullo; R A Anderson; C Chany; D P Waller; L J D Zaneveld; M E Klotman
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Developing an asymptomatic mucosal herpes vaccine: the present and the future.

Authors:  Gargi Dasgupta; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

7.  Longitudinal Characterization of Herpes Simplex Virus (HSV) Isolates Acquired From Different Sites in an Immune-Compromised Child: A New HSV Thymidine Kinase Mutation Associated With Resistance.

Authors:  Andrew H Karaba; Laura K Cohen; Taly Glaubach; Sarah J Kopp; Jennifer L Reichek; Hawke H Yoon; Xiaotian T Zheng; William J Muller
Journal:  J Pediatric Infect Dis Soc       Date:  2012-05-03       Impact factor: 3.164

8.  NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2.

Authors:  Sara Sinha; Natalia Cheshenko; Robert I Lehrer; Betsy C Herold
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression.

Authors:  Natalia Cheshenko; Janie B Trepanier; Martha Stefanidou; Niall Buckley; Pablo Gonzalez; William Jacobs; Betsy C Herold
Journal:  FASEB J       Date:  2013-03-18       Impact factor: 5.191

10.  Reconsideration of viral protein immunoblotting for differentiation of human herpes simplex viruses.

Authors:  Robert N Bowles; Jamie C Yedowitz; John A Blaho
Journal:  Diagn Microbiol Infect Dis       Date:  2008-07-17       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.